CRBU Relative Valuation
CRBU's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRBU is overvalued; if below, it's undervalued.
Historical Valuation
Caribou Biosciences Inc (CRBU) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.11. The fair price of Caribou Biosciences Inc (CRBU) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.94
Fair
-1.43
PE
1Y
3Y
5Y
Trailing
Forward
-0.24
EV/EBITDA
Caribou Biosciences Inc. (CRBU) has a current EV/EBITDA of -0.24. The 5-year average EV/EBITDA is -1.88. The thresholds are as follows: Strongly Undervalued below -10.88, Undervalued between -10.88 and -6.38, Fairly Valued between 2.61 and -6.38, Overvalued between 2.61 and 7.11, and Strongly Overvalued above 7.11. The current Forward EV/EBITDA of -0.24 falls within the Historic Trend Line -Fairly Valued range.
-0.30
EV/EBIT
Caribou Biosciences Inc. (CRBU) has a current EV/EBIT of -0.30. The 5-year average EV/EBIT is -1.88. The thresholds are as follows: Strongly Undervalued below -10.82, Undervalued between -10.82 and -6.35, Fairly Valued between 2.59 and -6.35, Overvalued between 2.59 and 7.06, and Strongly Overvalued above 7.06. The current Forward EV/EBIT of -0.30 falls within the Historic Trend Line -Fairly Valued range.
17.57
PS
Caribou Biosciences Inc. (CRBU) has a current PS of 17.57. The 5-year average PS is 31.45. The thresholds are as follows: Strongly Undervalued below -21.23, Undervalued between -21.23 and 5.11, Fairly Valued between 57.79 and 5.11, Overvalued between 57.79 and 84.13, and Strongly Overvalued above 84.13. The current Forward PS of 17.57 falls within the Historic Trend Line -Fairly Valued range.
-1.30
P/OCF
Caribou Biosciences Inc. (CRBU) has a current P/OCF of -1.30. The 5-year average P/OCF is -5.03. The thresholds are as follows: Strongly Undervalued below -19.03, Undervalued between -19.03 and -12.03, Fairly Valued between 1.98 and -12.03, Overvalued between 1.98 and 8.98, and Strongly Overvalued above 8.98. The current Forward P/OCF of -1.30 falls within the Historic Trend Line -Fairly Valued range.
-1.15
P/FCF
Caribou Biosciences Inc. (CRBU) has a current P/FCF of -1.15. The 5-year average P/FCF is -4.15. The thresholds are as follows: Strongly Undervalued below -18.48, Undervalued between -18.48 and -11.32, Fairly Valued between 3.01 and -11.32, Overvalued between 3.01 and 10.18, and Strongly Overvalued above 10.18. The current Forward P/FCF of -1.15 falls within the Historic Trend Line -Fairly Valued range.
Caribou Biosciences Inc (CRBU) has a current Price-to-Book (P/B) ratio of 1.28. Compared to its 3-year average P/B ratio of 0.99 , the current P/B ratio is approximately 29.18% higher. Relative to its 5-year average P/B ratio of 0.85, the current P/B ratio is about 49.53% higher. Caribou Biosciences Inc (CRBU) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -59.68%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -43.73% , the current FCF yield is about -100.00% lower.
1.28
P/B
Median3y
0.99
Median5y
0.85
-73.47
FCF Yield
Median3y
-59.68
Median5y
-43.73
Competitors Valuation Multiple
The average P/S ratio for CRBU's competitors is 0.00, providing a benchmark for relative valuation. Caribou Biosciences Inc Corp (CRBU) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 8.60%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CRBU increased by 22.01% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.81 to -1.14.
The secondary factor is the Revenue Growth, contributed 8.60%to the performance.
Overall, the performance of CRBU in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Caribou Biosciences Inc (CRBU) currently overvalued or undervalued?
What is Caribou Biosciences Inc (CRBU) fair value?
How does CRBU's valuation metrics compare to the industry average?
What is the current P/B ratio for Caribou Biosciences Inc (CRBU) as of Dec 05 2025?
What is the current FCF Yield for Caribou Biosciences Inc (CRBU) as of Dec 05 2025?
What is the current Forward P/E ratio for Caribou Biosciences Inc (CRBU) as of Dec 05 2025?